论文部分内容阅读
ｏｍａｐａｔｒｉｌａｔ是布迈－施贵宝（ＢＭＳ）公司正在开发的治疗高血压和心衰的新产品，为第一个新一类血管肽酶抑制剂，是一种对血管紧张素转化酶（ＡＣＥ）和中性内肽酶（ＮＥＰ）起双重抑制作用的单分子物质。ＡＣＥ可将血管紧张素Ⅰ转化为血管紧张素Ⅱ，血管紧张素Ⅱ
omapatrilat is a new product under development for the treatment of hypertension and heart failure by the Bamy-Bristol-Myers Squibb (BMS) company. It is the first new class of vasopeptidase inhibitors, an inhibitor of angiotensin-converting enzyme (ACE) and Sexual endopeptidase (NEP) plays a dual inhibitory effect of single-molecule substances. ACE can convert angiotensin Ⅰ into angiotensin Ⅱ and angiotensin Ⅱ